SHANGHAI, June 18, 2025 /PRNewswire/ — WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that the Science Based Targets initiative (SBTi) has approved WuXi AppTec’s near-term science-based emissions reduction targets. The validation of these targets affirms that the Company’s planned reduction in greenhouse gas (GHG) emissions aligns with the goal of limiting global temperature rise to 1.5°C, underscoring WuXi AppTec’s commitment to meaningful action for a more sustainable future.
With the SBTi validation, WuXi AppTec commits to reducing absolute Scope 1 and 2 GHG emissions by 42% by 2030, based on 2024 levels. The Company also aims to reduce absolute Scope 3 GHG emissions from purchased goods and services and fuel- and energy-related activities by 25% within the same timeframe (Scopes 1, 2, 3 are internationally recognized ways of classifying greenhouse gas emissions).
The SBTi enables companies and financial institutions worldwide to play a pivotal role in combating the climate crisis. It develops standards, tools, and guidance that enable organizations to set GHG emissions reduction targets in line with what is required to keep global heating below catastrophic levels and achieve net-zero by 2050.
“SBTi validation of WuXi AppTec’s near-term targets marks an important milestone in our Company’s sustainability journey,” said Dr. Steve Yang, Co-CEO of WuXi AppTec and Chairman of WuXi AppTec’s ESG Committee. “This recognition underscores our commitment to corporate social responsibility, scientific rigor, and transparency of our greenhouse gas emission reduction efforts. WuXi AppTec is dedicated to supporting our customers in delivering innovative therapies to patients worldwide, working together toward a healthier and more sustainable future.”
To achieve these targets, WuXi AppTec is implementing measures such as process optimization, equipment upgrades, infrastructure renovation, and technological innovations to enhance energy efficiency. The Company is also increasing its use of renewable energy by purchasing green electricity and installing photovoltaic power generation facilities. These efforts aim to progressively reduce carbon emissions within operational boundaries. Furthermore, WuXi AppTec is collaborating with suppliers to reduce absolute GHG emissions associated with purchased goods and services, fostering progress toward a low-carbon supply chain.
As an enabler of innovation, a trusted partner, and a contributor to the global pharmaceutical and life sciences industry, WuXi AppTec strategically integrates sustainability priorities like most of the customers into its global business operations. The Company has received an AA rating in the MSCI ESG ratings for four consecutive years, inclusion in the Dow Jones Sustainability Index (DJSI) for the same duration, and an A- Leadership rating in the CDP Climate Change rating for three consecutive years. WuXi AppTec has also been recognized as an Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics and received an A Leadership rating in the CDP Water Security rating, as well as a Gold Medal in the EcoVadis sustainability rating.
To further its commitment to sustainability, WuXi AppTec has joined the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI) as a supplier partner.
About WuXi AppTec
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024 and its open-access platform is enabling around 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.”
